Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C10H14N2 |
Molecular Weight | 162.2316 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCC[C@H]1C2=CN=CC=C2
InChI
InChIKey=SNICXCGAKADSCV-JTQLQIEISA-N
InChI=1S/C10H14N2/c1-12-7-3-5-10(12)9-4-2-6-11-8-9/h2,4,6,8,10H,3,5,7H2,1H3/t10-/m0/s1
Molecular Formula | C10H14N2 |
Molecular Weight | 162.2316 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: www.inchem.org/documents/pims/chemical/nicotine.htmCurator's Comment: description was created based on several sources, including
https://cancercontrol.cancer.gov/brp/tcrb/monographs/1/index.html
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2928221/
Sources: www.inchem.org/documents/pims/chemical/nicotine.htm
Curator's Comment: description was created based on several sources, including
https://cancercontrol.cancer.gov/brp/tcrb/monographs/1/index.html
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2928221/
Nicotine is a natural alkaloid obtained from the dried leaves and stems of the nightshade family of pants, such as Nicotiana tabacum and Nicotiana rustica, where it occurs in concentrations of 0.5-8%. Cigarette tobacco varies in its nicotine content, but common blends contain 15-25 mg per cigarette, with a current trend towards lower levels. Nicotine is highly addictive substance, it exhibits a stimulant effect when adsorbed at 2 mg. Administration of higher doses could be harmful. Action of nicotine is mediated by nicotinic cholinergic receptors. Nicotine binds to the interface between two subunits of the receptors, opens the channel and allows the entry of sodium or calcium. The principal mediator of nicotine dependence is α4β2 nicotine receptor.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1907589 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15528443 |
7.9 null [pKi] | ||
Target ID: CHEMBL1907594 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22148173 |
260.0 nM [Ki] | ||
Target ID: CHEMBL2492 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15528443 |
3.0 µM [Ki] | ||
Target ID: CHEMBL2109238 |
|||
Target ID: Nicotinic acetylcholine receptors |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | NICORETTE Approved UseReduces withdrawal symptoms, including nicotine craving associated with quitting smoking Launch Date4.42713604E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12 ng/mL |
1 mg single, nasal dose: 1 mg route of administration: Nasal experiment type: SINGLE co-administered: |
NICOTINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6 ng × h/mL |
1 mg single, nasal dose: 1 mg route of administration: Nasal experiment type: SINGLE co-administered: |
NICOTINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3 min |
1 mg single, nasal dose: 1 mg route of administration: Nasal experiment type: SINGLE co-administered: |
NICOTINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
95% |
1 mg single, nasal dose: 1 mg route of administration: Nasal experiment type: SINGLE co-administered: |
NICOTINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
6 mg single, oral Highest studied dose |
healthy, 19 - 49 years n = 44 Health Status: healthy Condition: adult smokers Age Group: 19 - 49 years Sex: M+F Population Size: 44 Sources: |
Disc. AE: Bradycardia... AEs leading to discontinuation/dose reduction: Bradycardia (1 patient) Sources: |
4 mg single, oral Studied dose |
healthy, 19 - 49 years n = 44 Health Status: healthy Condition: adult smokers Age Group: 19 - 49 years Sex: M+F Population Size: 44 Sources: |
Disc. AE: Allergic dermatitis... AEs leading to discontinuation/dose reduction: Allergic dermatitis (1 patient) Sources: |
6 mg 1 times / hour steady, oral Highest studied dose Dose: 6 mg, 1 times / hour Route: oral Route: steady Dose: 6 mg, 1 times / hour Sources: |
healthy, 19 - 50 years n = 50 Health Status: healthy Condition: adult smokers Age Group: 19 - 50 years Sex: M+F Population Size: 50 Sources: |
Disc. AE: Hypersensitivity, Nausea... AEs leading to discontinuation/dose reduction: Hypersensitivity (1 patient) Sources: Nausea (1 patient) |
8 mg 1 times / hour steady, oral Highest studied dose Dose: 8 mg, 1 times / hour Route: oral Route: steady Dose: 8 mg, 1 times / hour Sources: |
healthy, 19 - 50 years n = 50 Health Status: healthy Condition: adult smokers Age Group: 19 - 50 years Sex: M+F Population Size: 50 Sources: |
Disc. AE: Depression, Nausea... AEs leading to discontinuation/dose reduction: Depression (1 patient) Sources: Nausea (grade 2-3, 2 patients) |
111 mg single, transdermal Overdose Dose: 111 mg Route: transdermal Route: single Dose: 111 mg Sources: |
healthy, 41 years n = 1 Health Status: healthy Condition: adult smoker Age Group: 41 years Sex: M Population Size: 1 Sources: |
Disc. AE: Death... AEs leading to discontinuation/dose reduction: Death (grade 5, 1 patient) Sources: |
84 mg 1 times / day steady, transdermal Highest studied dose Dose: 84 mg, 1 times / day Route: transdermal Route: steady Dose: 84 mg, 1 times / day Sources: |
healthy, adult n = 36 Health Status: healthy Condition: adult smokers Age Group: adult Sex: unknown Population Size: 36 Sources: |
Other AEs: Nausea... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Bradycardia | 1 patient Disc. AE |
6 mg single, oral Highest studied dose |
healthy, 19 - 49 years n = 44 Health Status: healthy Condition: adult smokers Age Group: 19 - 49 years Sex: M+F Population Size: 44 Sources: |
Allergic dermatitis | 1 patient Disc. AE |
4 mg single, oral Studied dose |
healthy, 19 - 49 years n = 44 Health Status: healthy Condition: adult smokers Age Group: 19 - 49 years Sex: M+F Population Size: 44 Sources: |
Hypersensitivity | 1 patient Disc. AE |
6 mg 1 times / hour steady, oral Highest studied dose Dose: 6 mg, 1 times / hour Route: oral Route: steady Dose: 6 mg, 1 times / hour Sources: |
healthy, 19 - 50 years n = 50 Health Status: healthy Condition: adult smokers Age Group: 19 - 50 years Sex: M+F Population Size: 50 Sources: |
Nausea | 1 patient Disc. AE |
6 mg 1 times / hour steady, oral Highest studied dose Dose: 6 mg, 1 times / hour Route: oral Route: steady Dose: 6 mg, 1 times / hour Sources: |
healthy, 19 - 50 years n = 50 Health Status: healthy Condition: adult smokers Age Group: 19 - 50 years Sex: M+F Population Size: 50 Sources: |
Depression | 1 patient Disc. AE |
8 mg 1 times / hour steady, oral Highest studied dose Dose: 8 mg, 1 times / hour Route: oral Route: steady Dose: 8 mg, 1 times / hour Sources: |
healthy, 19 - 50 years n = 50 Health Status: healthy Condition: adult smokers Age Group: 19 - 50 years Sex: M+F Population Size: 50 Sources: |
Nausea | grade 2-3, 2 patients Disc. AE |
8 mg 1 times / hour steady, oral Highest studied dose Dose: 8 mg, 1 times / hour Route: oral Route: steady Dose: 8 mg, 1 times / hour Sources: |
healthy, 19 - 50 years n = 50 Health Status: healthy Condition: adult smokers Age Group: 19 - 50 years Sex: M+F Population Size: 50 Sources: |
Death | grade 5, 1 patient Disc. AE |
111 mg single, transdermal Overdose Dose: 111 mg Route: transdermal Route: single Dose: 111 mg Sources: |
healthy, 41 years n = 1 Health Status: healthy Condition: adult smoker Age Group: 41 years Sex: M Population Size: 1 Sources: |
Nausea | 84 mg 1 times / day steady, transdermal Highest studied dose Dose: 84 mg, 1 times / day Route: transdermal Route: steady Dose: 84 mg, 1 times / day Sources: |
healthy, adult n = 36 Health Status: healthy Condition: adult smokers Age Group: adult Sex: unknown Population Size: 36 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: - |
no | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 245.0 |
minor | |||
Page: 245.0 |
minor | |||
Sources: https://molpharm.aspetjournals.org/content/72/3/761 Page: - |
no | |||
Page: - |
yes | |||
Page: 245.0 |
yes | |||
Page: - |
yes | |||
Page: 60.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/17909004/ Page: - |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/20876810/ Page: - |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/20876810/ Page: - |
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: - |
PubMed
Title | Date | PubMed |
---|---|---|
Cow's urine poisoning in Nigeria. Experimental observations in mice. | 1975 Jun |
|
Enhancement of haloperidol-induced catalepsy by nicotine: an investigation of possible mechanisms. | 2000 Nov |
|
Kynurenic acid does not protect against nicotine-induced seizures in mice. | 2000 Nov-Dec |
|
Prenatal nicotine exposure is associated with an increase in [125I]epibatidine binding in discrete cortical regions in rats. | 2000 Oct |
|
Effects of nicotine on the intervertebral disc: an experimental study in rabbits. | 2001 |
|
Chronic nicotine exposure reduces N-methyl-D-aspartate receptor-mediated damage in the hippocampus without altering calcium accumulation or extrusion: evidence of calbindin-D28K overexpression. | 2001 |
|
Effect of nicotine on fibroblast beta 1 integrin expression and distribution in vitro. | 2001 Apr |
|
Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. | 2001 Apr |
|
Formation of the quaternary ammonium-linked glucuronide of nicotine in human liver microsomes: identification and stereoselectivity in the kinetics. | 2001 Dec |
|
Nicotine inhibits UV-induced activation of the apoptotic pathway. | 2001 Dec 15 |
|
Tolerance to nicotine's effects in the elevated plus-maze and increased anxiety during withdrawal. | 2001 Feb |
|
Nicotine induced changes in gene expression by human coronary artery endothelial cells. | 2001 Feb 1 |
|
Nicotine self-administration and withdrawal: modulation of anxiety in the social interaction test in rats. | 2001 Jan |
|
Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. | 2001 Jan |
|
Cardiovascular effects of transdermal nicotine in mildly hypertensive smokers. | 2001 Jul |
|
Nicotine produces selective degeneration in the medial habenula and fasciculus retroflexus. | 2001 Jul 6 |
|
Nicotine metabolism and CYP2A6 allele frequencies in Koreans. | 2001 Jun |
|
Nicotinic regulation of c-fos and osteopontin expression in human-derived osteoblast-like cells and human trabecular bone organ culture. | 2001 Jun |
|
Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. | 2001 Jun |
|
Reversal of diminished inhibitory sensory gating in cocaine addicts by a nicotinic cholinergic mechanism. | 2001 Jun |
|
An immunotherapeutic program for the treatment of nicotine addiction: hapten design and synthesis. | 2001 Jun 15 |
|
A novel single nucleotide polymorphism altering stability and activity of CYP2a6. | 2001 Mar 2 |
|
Inhibition of nicotine-induced seizures in rats by combining vaccination against nicotine with chronic nicotine infusion. | 2001 May |
|
Smoking and balance: correlation of nicotine-induced nystagmus and postural body sway. | 2001 May 8 |
|
Comparison of cytochrome P450 2A6 polymorphism frequencies in Caucasians and African-Americans using a new one-step PCR-RFLP genotyping method. | 2001 Nov 30 |
|
Nicotine affects the signaling of the death pathway, reducing the response of head and neck cancer cell lines to DNA damaging agents. | 2001 Oct |
|
Nicotine induced seizures blocked by mecamylamine and its stereoisomers. | 2001 Oct 19 |
|
Activation of 5-HT(2C) receptors reduces the locomotor and rewarding effects of nicotine. | 2001 Sep |
|
Acute myocardial infarction soon after nicotine replacement therapy. | 2001 Sep |
|
Efficient enantiomeric synthesis of pyrrolidine and piperidine alkaloids from tobacco. | 2001 Sep 21 |
|
Nornicotine, a nicotine metabolite and tobacco alkaloid: desensitization of nicotinic receptor-stimulated dopamine release from rat striatum. | 2001 Sep 28 |
|
Fetal and adolescent nicotine administration: effects on CNS serotonergic systems. | 2001 Sep 28 |
|
[Acute confusional syndrome due to acute nicotine withdrawal]. | 2002 |
|
Molecular orbital calculations and nicotine metabolism: a rationale for experimentally observed metabolite ratios. | 2002 |
|
The relationship between hippocampal acetylcholine release and cholinergic convulsant sensitivity in withdrawal seizure-prone and withdrawal seizure-resistant selected mouse lines. | 2002 Aug |
|
Alcohol and nicotine reduce cell proliferation and enhance apoptosis in dentate gyrus. | 2002 Aug 27 |
|
Microsomal N-glucuronidation of nicotine and cotinine: human hepatic interindividual, human intertissue, and interspecies hepatic variation. | 2002 Dec |
|
An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. | 2002 Jan 11 |
|
Absence of alpha7-containing neuronal nicotinic acetylcholine receptors does not prevent nicotine-induced seizures. | 2002 Jan 31 |
|
Effects of whole deletion of CYP2A6 on nicotine metabolism in humans. | 2002 May |
|
Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. | 2002 Nov |
|
CYP2A6 genetic variation and potential consequences. | 2002 Nov 18 |
|
beta 2 nicotinic acetylcholine receptor subunit modulates protective responses to stress: A receptor basis for sleep-disordered breathing after nicotine exposure. | 2002 Oct 1 |
|
Lasting effects of adolescent nicotine exposure on the electroencephalogram, event related potentials, and locomotor activity in the rat. | 2002 Sep 20 |
|
Oral caffeine maintenance potentiates the reinforcing and stimulant subjective effects of intravenous nicotine in cigarette smokers. | 2003 Jan |
|
Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. | 2003 Jan 1 |
|
A functional role for nicotine in Bcl2 phosphorylation and suppression of apoptosis. | 2003 Jan 17 |
|
Nicotinic acetylcholine receptors and the regulation of neuronal signalling. | 2004 Jun |
|
Nicotine addiction. | 2010 Jun 17 |
|
How much nicotine kills a human? Tracing back the generally accepted lethal dose to dubious self-experiments in the nineteenth century. | 2014 Jan |
Patents
Sample Use Guides
Reduces withdrawal symptoms, including nicotine craving associated with quitting smoking, nicotine is available as a chewing gum, and is administered according to a schedule at doses 2-4 mg once every 2-4 hours. Nicotine is also available as a transdermal patch.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22148173
Functional activity of nicotine against hα4β2 nicotinic receptors was evaluated using the 86Rb+ ion flux assay in SH-EP1 cells, expressing hα4β2. The 86Rb+ efflux was measured using the “flip-plate” technique. Nicotine activated 86Rb+ efflux with EC50 of 290 nM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 22:39:31 UTC 2023
by
admin
on
Wed Jul 05 22:39:31 UTC 2023
|
Record UNII |
6M3C89ZY6R
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Related Record | Type |
---|
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C221
Created by
admin on Wed Jul 05 22:39:31 UTC 2023 , Edited by admin on Wed Jul 05 22:39:31 UTC 2023
|
||
|
LIVERTOX |
NBK548698
Created by
admin on Wed Jul 05 22:39:31 UTC 2023 , Edited by admin on Wed Jul 05 22:39:31 UTC 2023
|
||
|
WHO-ATC |
N07BA01
Created by
admin on Wed Jul 05 22:39:31 UTC 2023 , Edited by admin on Wed Jul 05 22:39:31 UTC 2023
|
||
|
NDF-RT |
N0000175706
Created by
admin on Wed Jul 05 22:39:31 UTC 2023 , Edited by admin on Wed Jul 05 22:39:31 UTC 2023
|
||
|
WHO-VATC |
QP53AX13
Created by
admin on Wed Jul 05 22:39:31 UTC 2023 , Edited by admin on Wed Jul 05 22:39:31 UTC 2023
|
||
|
WHO-VATC |
QN07BA01
Created by
admin on Wed Jul 05 22:39:31 UTC 2023 , Edited by admin on Wed Jul 05 22:39:31 UTC 2023
|
||
|
EPA PESTICIDE CODE |
56702
Created by
admin on Wed Jul 05 22:39:31 UTC 2023 , Edited by admin on Wed Jul 05 22:39:31 UTC 2023
|
||
|
NDF-RT |
N0000006496
Created by
admin on Wed Jul 05 22:39:31 UTC 2023 , Edited by admin on Wed Jul 05 22:39:31 UTC 2023
|
||
|
NCI_THESAURUS |
C73579
Created by
admin on Wed Jul 05 22:39:31 UTC 2023 , Edited by admin on Wed Jul 05 22:39:31 UTC 2023
|
||
|
NDF-RT |
N0000006496
Created by
admin on Wed Jul 05 22:39:31 UTC 2023 , Edited by admin on Wed Jul 05 22:39:31 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
D009538
Created by
admin on Wed Jul 05 22:39:31 UTC 2023 , Edited by admin on Wed Jul 05 22:39:31 UTC 2023
|
PRIMARY | |||
|
7407
Created by
admin on Wed Jul 05 22:39:31 UTC 2023 , Edited by admin on Wed Jul 05 22:39:31 UTC 2023
|
PRIMARY | |||
|
100000079991
Created by
admin on Wed Jul 05 22:39:31 UTC 2023 , Edited by admin on Wed Jul 05 22:39:31 UTC 2023
|
PRIMARY | |||
|
2585
Created by
admin on Wed Jul 05 22:39:31 UTC 2023 , Edited by admin on Wed Jul 05 22:39:31 UTC 2023
|
PRIMARY | |||
|
C691
Created by
admin on Wed Jul 05 22:39:31 UTC 2023 , Edited by admin on Wed Jul 05 22:39:31 UTC 2023
|
PRIMARY | |||
|
Nicotine replacement therapy
Created by
admin on Wed Jul 05 22:39:31 UTC 2023 , Edited by admin on Wed Jul 05 22:39:31 UTC 2023
|
PRIMARY | |||
|
17688
Created by
admin on Wed Jul 05 22:39:31 UTC 2023 , Edited by admin on Wed Jul 05 22:39:31 UTC 2023
|
PRIMARY | |||
|
89594
Created by
admin on Wed Jul 05 22:39:31 UTC 2023 , Edited by admin on Wed Jul 05 22:39:31 UTC 2023
|
PRIMARY | |||
|
1107
Created by
admin on Wed Jul 05 22:39:31 UTC 2023 , Edited by admin on Wed Jul 05 22:39:31 UTC 2023
|
PRIMARY | |||
|
NICOTINE
Created by
admin on Wed Jul 05 22:39:31 UTC 2023 , Edited by admin on Wed Jul 05 22:39:31 UTC 2023
|
PRIMARY | |||
|
CHEMBL3
Created by
admin on Wed Jul 05 22:39:31 UTC 2023 , Edited by admin on Wed Jul 05 22:39:31 UTC 2023
|
PRIMARY | |||
|
DB00184
Created by
admin on Wed Jul 05 22:39:31 UTC 2023 , Edited by admin on Wed Jul 05 22:39:31 UTC 2023
|
PRIMARY | |||
|
DTXSID1020930
Created by
admin on Wed Jul 05 22:39:31 UTC 2023 , Edited by admin on Wed Jul 05 22:39:31 UTC 2023
|
PRIMARY | |||
|
SUB14645MIG
Created by
admin on Wed Jul 05 22:39:31 UTC 2023 , Edited by admin on Wed Jul 05 22:39:31 UTC 2023
|
PRIMARY | |||
|
Nicotine
Created by
admin on Wed Jul 05 22:39:31 UTC 2023 , Edited by admin on Wed Jul 05 22:39:31 UTC 2023
|
PRIMARY | |||
|
54-11-5
Created by
admin on Wed Jul 05 22:39:31 UTC 2023 , Edited by admin on Wed Jul 05 22:39:31 UTC 2023
|
PRIMARY | |||
|
nicotine
Created by
admin on Wed Jul 05 22:39:31 UTC 2023 , Edited by admin on Wed Jul 05 22:39:31 UTC 2023
|
PRIMARY | |||
|
SUB30160
Created by
admin on Wed Jul 05 22:39:31 UTC 2023 , Edited by admin on Wed Jul 05 22:39:31 UTC 2023
|
PRIMARY | |||
|
1920
Created by
admin on Wed Jul 05 22:39:31 UTC 2023 , Edited by admin on Wed Jul 05 22:39:31 UTC 2023
|
PRIMARY | |||
|
M7879
Created by
admin on Wed Jul 05 22:39:31 UTC 2023 , Edited by admin on Wed Jul 05 22:39:31 UTC 2023
|
PRIMARY | Merck Index | ||
|
5065
Created by
admin on Wed Jul 05 22:39:31 UTC 2023 , Edited by admin on Wed Jul 05 22:39:31 UTC 2023
|
PRIMARY | |||
|
6M3C89ZY6R
Created by
admin on Wed Jul 05 22:39:31 UTC 2023 , Edited by admin on Wed Jul 05 22:39:31 UTC 2023
|
PRIMARY | |||
|
200-193-3
Created by
admin on Wed Jul 05 22:39:31 UTC 2023 , Edited by admin on Wed Jul 05 22:39:31 UTC 2023
|
PRIMARY | |||
|
6M3C89ZY6R
Created by
admin on Wed Jul 05 22:39:31 UTC 2023 , Edited by admin on Wed Jul 05 22:39:31 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
||
|
TARGET -> AGONIST |
NICOTINE IS AN ANTIHERBIVORY ALKALOID AND POTENT PARASYMPATHOMIMETIC STIMULANT AND FOUND IN PLANTS, MOSTLY THOSE IN THE NIGHTSHADE FAMILY. NICOTINE ACTS AS A RECEPTOR AGONIST AT MOST NICOTINIC ACETYLCHOLINE RECEPTORS (NACHRS), EXCEPT AT TWO NICOTINIC RECEPTOR SUBUNITS (NACHR.ALPHA.9 AND NACHR.ALPHA.10) WHERE IT ACTS AS A RECEPTOR ANTAGONIST.
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
USP
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
SALT/SOLVATE -> PARENT | |||
|
BINDER->LIGAND |
BINDING
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> INHIBITOR |
|
||
|
SUB_CONCEPT->SUBSTANCE | |||
|
SALT/SOLVATE -> PARENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
Nicotine (mg/cigarette)
Domestic = 12.6 SD(1.6)
Imported = 11.1 SD(2.2)
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
LABELED -> NON-LABELED | |||
|
INHIBITOR -> TARGET |
BINDS TO NICOTINE PREVENTS ACTION
|
||
|
SUB_CONCEPT->SUBSTANCE | |||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE LESS ACTIVE -> PARENT |
75% is converted into cotintine which is further metabolized.
MAJOR
PLASMA; URINE
|
||
|
METABOLITE -> PARENT |
circulating nicotine is metabolized to cotinine by cytochrome P450 and aldehyde oxidase
MAJOR
|
||
|
METABOLITE -> PARENT |
in animals both N-oxide isomers form, in humans only the transisomers form.
MAJOR
URINE
|
||
|
METABOLITE -> PARENT |
The extent of nicotine N-glucuronidation by African Americans is significantly lower than by Whites.
|
||
|
METABOLITE -> PARENT |
PLASMA; URINE
|
||
|
METABOLITE -> PARENT |
The extent of Cotinine N-glucuronidation by African Americans is significantly lower than by Whites.
|
||
|
METABOLITE INACTIVE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||